Tier	Biomarker	Alteration	Tumour Type	Drugs	Comments	Evidence
1	ALK	EML4-ALK Fusion, Fusions	Non-Small Cell Lung Cancer	Alectinib	PBS reimbursed if FISH positive	28586279, 28501140
1	ALK	EML4-ALK Fusion, Fusions	Non-Small Cell Lung Cancer	Ceritinib	PBS reimbursed if FISH positive	24670165
1	ALK	EML4-ALK Fusion, Fusions	Non-Small Cell Lung Cancer	Crizotinib	PBS reimbursed if FISH positive	20979469
1	CD20	Protein expression	Non-Hodgkin’s Lymphoma; Chronic lymphocytic leukaemia; Acute lymphoblastic leukaemia; Hodgkin’s Lymphoma	Rituximab	PBS reimbursed. Reference non-exhaustive	11807147, 20888994
1	EGFR	Exon 19 deletion, L858R, Exon 21 mutation	Non-Small Cell Lung Cancer	Afatinib	PBS reimbursed, LUX-Lung 6, LUX-Lung 7	23816960, 24439929, 27083334
1	EGFR	Exon 19 deletion, L858R, Exon 21 mutation	Non-Small Cell Lung Cancer	Erlotinib	PBS reimbursed, OPTIMAL	16014882, 16014883
1	EGFR	Exon 19 deletion, L858R, Exon 21 mutation	Non-Small Cell Lung Cancer	Gefitinib	PBS reimbursed	15118125, 19692680, 20573926
1	EGFR	Exon 19 deletion, L858R, Exon 21 mutation	Non-Small Cell Lung Cancer	Osimertinib	PBS reimbursed, AURA3	27959700, 29151359
1	EGFR	G719, L861Q, S768I	Non-Small Cell Lung Cancer	Afatinib	PBS reimbursed. LUX-Lung 6	24439929
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib	PBS reimbursed. AURA3	27959700
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib		25264305
1B	ALK	EML4-ALK Fusion, Fusions 	Non-Small Cell Lung Cancer	Brigatinib	TGA approved. Not PBS reimbursed; FDA approved	30280657
1B	ALK	EML4-ALK Fusion, Fusions 	Non-Small Cell Lung Cancer	Lorlatinib	TGA approved. Not PBS reimbursed. Ph3 CROWN	30413378, 10.1016/j.annonc.2020.08.2282
1B	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib	TGA approved. Not PBS reimbursed	29072975
1B	CD20	Protein expression	Non-Hodgkin’s Lymphoma	Ibrutinib	1+ prior therapy with an anti-CD20 antibody-containing regimen	28167659
1B	CD274+EGFR+ALK	CD274:Protein expression and NOT EGFR:oncogenic mutation and NOT ALK:fusion	Non-small cell lung cancer	Pembrolizumab	First line monotherapy	27718847
1B	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib	TGA approved; Not PBS Reimbursed	28183697, 10.1200/jco.2015.33.15_suppl.2517
1B	ROS1	Fusions	Non-Small Cell Lung Cancer	Lorlatinib	Not TGA approved	29074098
2	CD274	Protein expression	Non-Small Cell Lung Cancer	Cemiplimab	EMPOWER-Lung 1. CPS &gt;= 50	10.1016/j.annonc.2020.08.2285
2	CD274+EGFR+ALK	CD274:Protein expression and NOT EGFR:oncogenic mutation and NOT ALK:fusion	Non-small cell lung cancer	Atezolizumab	Not TGA approved; FDA approved; IMPower110	10.1093/annonc/mdz293
2	CD274+EGFR+ALK	CD274:Protein expression and NOT EGFR:oncogenic mutation and NOT ALK:fusion	Non-small cell lung cancer	Nivolumab + Ipilimumab	Not TGA approved; FDA approved; Checkmate 227	31562796
2	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Afatinib; Gefitinib; Erlotinib	Not explicitly TGA listed.	27413714, 10.1200/JCO.2019.37.15_suppl.e20593
2	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Apatinib + Gefitinib 	Apatinib not TGA or FDA approved. ACTIVE Phase 3 trial.	10.1016/j.annonc.2020.08.2283
2	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Dacomitinib	Not TGA approved. ARCHER 1009/1050	28958502, 25439691
2	EGFR	G719, L861Q, S768I	Non-Small Cell Lung Cancer	Erlotinib; Gefitinib	Intermediate response to 1G TKI with resistance data	27413714, 28184913
2	MET	Amplification, D1010, Exon 14 Deletion, Exon 14 splicing mutation, Y1003	Non-Small Cell Lung Cancer	Crizotinib	Not TGA approved; FDA orphan drug indication	26729443, 10.1200/jco.2014.32.15_suppl.8001
2	MET	Amplification, Exon 14 Deletion, Exon 14 splicing mutation, Exon 14 skipping mutation	Non-Small Cell Lung Cancer	Capmatinib	Not TGA approved; FDA approved; GEOMETRY mono-1 	32877583, 10.1200/JCO.2019.37.15_suppl.9004
2	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib	Not TGA approved. LIBRETTO-001. 1L ORR 85%	32846061, 10.1200/JCO.2020.38.15_suppl.3584
3	ALK	C1156Y, C1156T, L1196M	Non-Small Cell Lung Cancer	Ensartinib		28122866
3	ALK	C1156Y, C1156T, L1196M	Non-Small Cell Lung Cancer	Entrectinib		28122866
3	ALK	EML4-ALK Fusion, Fusions	Non-Small Cell Lung Cancer	Ensartinib		31628085
3	ALK	EML4-ALK Fusion, Fusions	Non-Small Cell Lung Cancer	Entrectinib		10.1200/jco.2015.33.15_suppl.2517
3	ALK	I1151ins, L1152P, L1152R, C1156Y, C1156T, F1174C, F1174L, F1174V, L1196M, S1206C, S1206Y, G1269A, G1269S	Non-Small Cell Lung Cancer	Brigatinib		28122866
3	ALK	I1151ins, L1152P, L1152R, C1156Y, C1156T, I1171T, I1171N, I1171S, F1174C, F1174L, F1174V, L1196M, G1202R, S1206C, S1206Y, E1210K, G1269A, G1269S	Non-Small Cell Lung Cancer	Lorlatinib		28122866
3	ALK	I1171T, I1171N, L1196M, S1206C, S1206Y, G1269A, G1269S	Non-Small Cell Lung Cancer	Ceritinib		28122866
3	ALK	L1152P, L1152R, C1156Y, C1156T, F1174C, F1174L, F1174V, L1196M, S1206C, S1206Y, G1269A, G1269S	Non-Small Cell Lung Cancer	Alectinib		28122866
3	ALK	L1198F	Non-Small Cell Lung Cancer	Crizotinib		26698910, 28122866 
3	CD274	Protein expression	Non-small cell lung cancer	Nivolumab	First line monotherapy. Second line treatment is PD-L1 agnostic	28407039; 29522162
3	EGFR	C797S, C797G	Non-Small Cell Lung Cancer	Erlotinib; Gefitinib		32206559
3	EGFR	Exon 19 deletion, L858R	Non-Small Cell Lung Cancer	Amivantamab + Lazertinib	ORR 36% 15PR 1CR in osimertinib resistance cohort. ORR 100% treatment naive	10.1016/j.annonc.2020.08.1572
3	EGFR	Exon 19 insertion	Non-Small Cell Lung Cancer	Erlotinib; Gefitinib		28089594
3	EGFR	Exon 20 insertion	Non-Small Cell Lung Cancer	Poziotinib	ZENITH20. ORR point not met but overall tumor reduction seen. AACR:2020 CT081	NCT03318939
3	EGFR	Exon 20 insertion	Non-Small Cell Lung Cancer	TAK-788	AACR 2020	NCT02716116
3	EGFR	S768I, A767_V769dup, P772dupDNP, S768_D770dup, D770insG, D770insY, H773Y, N771insH, D770delinsGY	Non-Small Cell Lung Cancer	Poziotinib		29686424
3	EGFR+MET	EGFR:oncogenic mutation and MET:amplification	Non-Small Cell Lung Cancer	Osimertinib + Savolitinib	Phase 1B TATTON. Significant ORR	32027846, 10.1158/1538-7445.AM2019-CT032
3	ERBB2	A775_G776insYVMA, G776ins, G776R, G776C, P780_Y781insGSP, V777L	Non-Small Cell Lung Cancer	Pyrotinib	NCT02834936	32614698
3	ERBB2	G778_P780dup	Non-Small Cell Lung Cancer	Afatinib; Dacomitinib; Pyrotinib; Poziotinib		32036069
3	ERBB2	Kinase domain mutation	Non-Small Cell Lung Cancer	Fam-trastuzumab deruxtecan-nxki	DESTINY-Lung01	10.1200/JCO.2020.38.15_suppl.9504
3	ERBB2	Oncogenic mutations, A775_G776insYVMA, exon 20 insertion	Non-Small Cell Lung Cancer	Pyrotinib		30596880
3	ERBB2	Oncogenic mutations, V659E, A775_G776insYVMA, G778_P780dup, G778insCPG, G776delinsVC, exon 20 insertion	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine	Not TGA approved. OncoKB LOE 2. 	30206164, 29989854
3	KRAS	G12C	Non-Small Cell Lung Cancer	Sotorasib	CODEBREAK 100 ORR 32.2%	32955176, 10.1016/j.jtho.2019.09.020
3	KRAS	G12C	Non-Small Cell Lung Cancer; Colorectal Cancer; Solid tumours	Adagrasib	KRYSTAL-1. Combined Phase 1&amp;2. ORR 45% (NSCLC), 17% (CRC)	10.1016/S0959-8049(20)31076-5
3	KRAS	Oncogenic mutations	Non-Small Cell Lung Cancer	Selumetinib + Docetaxel	Ph2 ORR 37%. Negative Ph 3 SELECT-1	23200175, 28492898
3	MET	Amplification	Non-Small Cell Lung Cancer	Capmatinib	GEOMETRY mono-1 study	10.1200/JCO.2020.38.15_suppl.9509
3	MET	Exon 14 Deletion, Exon 14 splicing mutation, Exon 14 skipping mutation	Non-Small Cell Lung Cancer	Crizotinib		31932802
3	MET	Exon 14 Deletion, Exon 14 splicing mutation, Exon 14 skipping mutation	Non-Small Cell Lung Cancer	Savolitinib		10.1158/1538-7445.AM2019-CT031
3	MET	Exon 14 Deletion, Exon 14 splicing mutation, Exon 14 skipping mutation	Non-Small Cell Lung Cancer	Tepotinib	VISION trial. ORR 48%. All lines of therapy.	32469185, 10.1016/j.jtho.2018.08.299
3	MET+EGFR	MET:amplification and EGFR:exon 19 deletion, MET:amplification and EGFR:L858R	Non-Small Cell Lung Cancer	Capmatinib + Gefitinib		30156984
3	MET+EGFR	MET:amplification and EGFR:exon 19 deletion, MET:amplification and EGFR:L858R	Non-Small Cell Lung Cancer	Tepotinib + Gefitinib	INSIGHT	32479794
3	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib	Not TGA approved. Single-arm phase 2. ORR 28%	27825636
3	RET	Fusions	Non-Small Cell Lung Cancer	Pralsetinib	Not TGA approved. ARROW	10.1200/JCO.2019.37.15_suppl.9008
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib	Not TGA approved. ORR 18%. OncoKB LOE 2	27803005
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib	LURET. Single-arm phase 2. ORR 47%. PFS 4.7mo	27825636
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib	Single-arm phase 2. ORR 18%. PFS 4.5mo	27803005
3	RET	Fusions	Non-Small Cell Lung Cancer	Lenvatinib	Single-arm phase 2. ORR 16%. PFS 7.3mo	31710864
3	ROS1	Fusion, G2032R	Non-Small Cell Lung Cancer	Repotrectinib	Exceptional Phase 1 activities (ORR 90%)	10.1200/JCO.2019.37.15_suppl.9011
3	ROS1	Fusions	Non-Small Cell Lung Cancer	Ceritinib	Positive phase 2 trial.	28520527
3	Tumour Mutational Burden	High	Non-small cell lung cancer	Durvalumab + Tremelimumab	MYSTIC trial	32271377
4	ALK	Amplification, protein expression	Non-Small Cell Lung Cancer	Ensartinib		31628085, 25724526
4	ALK	T1151, C1156Y, F1174C, F1174L, F1174V, G1269A, L1196M, S1206R	Non-Small Cell Lung Cancer	Ensartinib		31857951
4	ARAF	S214C	Non-Small Cell Lung Cancer	Sorafenib	Single case report. OncoKB LOE 3	24569458
4	ATM	Protein expression	Non-Small Cell Lung Cancer	AZD1390 + Radiotherapy		29938225
4	BCL2	Amplification	Non-Small Cell Lung Cancer	Venetoclax	Downgraded; Preclinical data only	29118061
4	CDKN2A	Loss of protein expression	Non-Small Cell Lung Cancer	Abemaciclib; Palbociclib	Cytostatic	27217383, 30647837
4	CDKN2A	Oncogenic mutations	Non-Small Cell Lung Cancer	Palbociclib	TAPUR. N=28. 1 PR. 6 SD	10.1200/JCO.2019.37.15_suppl.9041
4	CEACAM5	Overexpression	Non-Small Cell Lung Cancer	SAR408701		10.1200/JCO.2020.38.15_suppl.9505
4	EGFR	Amplification	Non-Small Cell Lung Cancer	Afatinib	Poor ORR 4/43 (9%) without mutation	25514804
4	EGFR	Amplification	Non-Small Cell Lung Cancer	Erlotinib	Retrospective study	30284706
4	EGFR	C797S, Exon 20 insertion	Non-Small Cell Lung Cancer	Amivantamab		10.1200/JCO.2019.37.15_suppl.9009, 10.1200/JCO.2020.38.15_suppl.9512 
4	EGFR	EGFR-RAD51 Fusion, EGFR-PURB fusion	Non-Small Cell Lung Cancer	Erlotinib		29290255, 27413714, 27102076
4	EGFR	Exon 18 deletion, Exon 18 mutation	Non-Small Cell Lung Cancer	Erlotinib; Gefitinib; Osimertinib	OncoKB LOE 3	26206867
4	EGFR	Exon 19 deletion and amplification; L858R and amplification; Exon 21 mutation  and amplification	Non-Small Cell Lung Cancer	Osimertinib + Necitumumab	ORCHARD trial	NCT03944772, NCT02496663
4	EGFR	Exon 20 insertion	Non-Small Cell Lung Cancer	Amivantamab	CHRYSALIS. ORR 36%	32414908, 10.1200/JCO.2020.38.15_suppl.9512
4	EGFR	Exon 20 mutation	Non-Small Cell Lung Cancer	EGFR inhibitor,exon 20 selective   	Review article	30854234
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib; Erlotinib; Gefitinib	OncoKB LOE 3	30255937, 19915609, 26286086
4	EGFR	L718V	Non-Small Cell Lung Cancer	Afatinib	Case report. Concomitant L858 and loss of T790M	29571986
4	EGFR	L747P, L747S	Non-Small Cell Lung Cancer	Afatinib	Retrospective sample	31200815
4	EGFR	L747S, D761Y, T854A	Non-Small Cell Lung Cancer	Afatinib; Osimertinib	Cell line study	28424065
4	EGFR	L833V	Non-Small Cell Lung Cancer	Gefitinib	Case report	21422421
4	EGFR	Overexpression	Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma	Serclutamab Talirine		10.1200/JCO.2020.38.15_suppl.TPS3649
4	EGFR	T790M and C797S and T790M-C797S trans-allelic conformation	Non-small cell lung cancer	Erlotinib + Osimertinib		31075545
4	EGFR+ALK	EGFR:oncogenic mutation and ALK:fusion	Non-Small Cell Lung Cancer	Osimertinib + Crizotinib; Osimertinib + Alectinib	Two case reports	30957057
4	EGFR+ERBB2	EGFR:oncogenic mutation and ERBB2:amplification	Non-Small Cell Lung Cancer	Osimertinib + Ado-Trastuzumab Emtansine		NCT03784599
4	EGFR+MET	EGFR:oncogenic mutation and MET:amplification and NOT EGFR:T790M	Non-Small Cell Lung Cancer	Gefitinib + Savolitinib		30156984
4	EGFR+MET	EGFR:T790M and MET:amplification	Non-Small Cell Lung Cancer	Osimertinib + Crizotinib	Case reports	28274743, 30881166, 31157314
4	EGFR+RET	EGFR:oncogenic mutation and RET:fusion	Non-Small Cell Lung Cancer	Osimertinib + Pralsetinib	Two case reports	30257958
4	EGFR+ROS1	EGFR:oncogenic mutation and ROS1:fusion	Non-Small Cell Lung Cancer	Osimertinib + Crizotinib	Case report	29935846
4	ERBB2	D769H, D769Y, L755S, V777L, L755P, A775_G776insYVMA, Exon 20 insertion, L786V, V842I, L869R	Solid tumours; Non-Small Cell Lung Cancer	Poziotinib	Cell-line evidence	31588020
4	ERBB2	D769H, D769Y, L755S, V777L, L755P, L786V, V842I, L869R	Solid tumours; Non-Small Cell Lung Cancer	Afatinib; Dacomitinib; Neratinib		31588020
4	ERBB2	D769H, D769Y, V777L	Solid tumours; Non-Small Cell Lung Cancer	Lapatinib		31588020
4	ERBB2	D769H, D769Y, V777L, L786V, V842I, L869R 	Solid tumours; Non-Small Cell Lung Cancer	Pyrotinib		31588020
4	ERBB2	D769Y, D742N	Non-Small Cell Lung Cancer	Pyrotinib	The case report cannot confirm dual driver	32327210
4	ERBB2	Oncogenic mutations, A775_G776insYVMA, exon 20 insertion	Non-Small Cell Lung Cancer	Neratinib	Single responders in lung ca.	29420467
4	ERBB2	Overexpression, amplification	Non-Small Cell Lung Cancer	Fam-trastuzumab deruxtecan-nxki	DESTINY-Lung01, no data available yet. Hypothesis generating	10.1200/JCO.2020.38.15_suppl.9504
4	ERBB4	Oncogenic mutations	Non-small cell lung cancer; Melanoma	Lapatinib + Afatinib		29902295
4	EZH2	Oncogenic mutation, A677G, Y641N, Y641C, Y641H, Y641S, Y641F, Y646, A687V	Non-Hodgkin Lymphoma	Tazemetostat		24563539
4	FANCD2	Loss-of-function mutation, Oncogenic mutations	Non-Small Cell Lung Cancer	Veliparib	Cell line study only using FANCD2 knockout	25566506
4	KRAS	Oncogenic mutation	Non-Small Cell Lung Cancer	SHP2 inhibitor		29808006
4	KRAS	Oncogenic mutation	Non-Small Cell Lung Cancer	Trametinib	Phase II, ORR 12% but worse PFS than docetaxel	10.1200/jco.2013.31.15_suppl.8029
4	KRAS	Oncogenic mutation	Non-Small Cell Lung Cancer	Trametinib + Ponatinib	Intrinsic MEK resistance by FGFR1 activation	27338794, NCT03704688
4	KRAS+ERBB3	KRAS:Oncogenic mutations and ERBB3:Overexpression	Non-Small Cell Lung Cancer; Colorectal Cancer	Afatinib + Selumetinib	By ERBB3 overexpression	24685132
4	MAP2K1	Oncogenic mutations	Non-Small Cell Lung Cancer	Cobimetinib; Trametinib	OncoKB LOE 3	31715422
4	MET	Amplification	Non-Small Cell Lung Cancer	Tepotinib		NCT02864992
4	MET	Exon 14 deletion, Exon 14 splicing mutation,  Exon 14 skipping mutation, Y1003, D1010, amplifications, D1228, G1163	Non-Small Cell Lung Cancer	Cabozantinib	Cabozantinib has activities; Note MET IHC not a biomarker	30762593, 27825638, 27693535
4	MET	Fusions	Non-Small Cell Lung Cancer; Glioblastoma	Crizotinib	Case reports	29527595, 30339198, 27748748
4	MET+EGFR	MET:Alteration and EGFR:Oncogenic mutations	Non-Small Cell Lung Cancer	Amivantamab		10.1200/JCO.2019.37.15_suppl.9009
4	NOTCH3	Overexpression	Non-small cell lung cancer	Gamma secretase inhibitor	Pre-clinical evidence	17804716
4	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib	Not TGA approved. Case reports only	23533264, 30653139
4	RET	RET fusions and NOT KIF5B-RET fusion	Non-Small Cell Lung Cancer	Agerafenib		31710864
4	ROS1	Fusions	Non-Small Cell Lung Cancer	AZD3463		26372962
4	ROS1	Fusions	Non-Small Cell Lung Cancer	Brigatinib	Not TGA approved	10.1200/PO.18.00267, 10.1158/1538-7445.AM2013-5655
4	ROS1	Fusions	Non-Small Cell Lung Cancer	Cabozantinib		32103985, NCT01639508
4	ROS1	Fusions	Non-Small Cell Lung Cancer	Ensartinib	In Phase 2 trial	NCT03608007
4	ROS1	Fusions; G2032R	Non-Small Cell Lung Cancer	DS-6051b		31399568
4	ROS1	G2032R	Non-Small Cell Lung Cancer	Cabozantinib	Cell-line evidence only	31395437, 25351743
R1	EGFR	Exon 20 insertion except A763_Y764insFQEA	Non-Small Cell Lung Cancer	Gefitinib; Neratinib; Afatinib; Erlotinib; Dacomitinib		21764376
R1	EGFR	T790M	Non-Small Cell Lung Cancer	Gefitinib; Neratinib; Afatinib; Erlotinib; Dacomitinib		18227510
R2	ALK	Amplification	Non-Small Cell Lung Cancer	Crizotinib		22323827, 22277784
R2	ALK	Fusion	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	ALK	G1202R, G1202del	Non-Small Cell Lung Cancer	Ensartinib		31857951
R2	ALK	G1202R, G1202del	Non-Small Cell Lung Cancer	Entrectinib		28122866
R2	ALK	G1202R, G1202del, D1203N, E1210K, E1210K and S1206C, E1210K and D1203N	Non-Small Cell Lung Cancer	Brigatinib		28122866, 28435288, 29935304
R2	ALK	I1151ins, L1152R, C1156Y, F1174L, F1174V, L1198F, L1196M, L1198P, G1202R, G1202del, S1206Y, G1269A, D1203N	Non-Small Cell Lung Cancer	Crizotinib		21030459, 28050598, 26698910, 28122866, 26568289, 22277784
R2	ALK	I1151ins, L1152R, L1152P, C1156Y, C1156T, F1174C, F1174L, F1174V, G1202R, G1202del	Non-Small Cell Lung Cancer	Ceritinib		28050598; 28122866;  26568289
R2	ALK	I1171T, I1171ins, I1171N, I1171S, V1180L, G1202R, G1202del	Non-Small Cell Lung Cancer	Alectinib		28050598; 28122866; 25228534; 26568289; 29935304
R2	ALK	L1198F and C1156Y	Non-Small Cell Lung Cancer	Lorlatinib		28122866
R2	BCL2L11	Deletion	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib		22426421
R2	BRAF	Oncogenic mutation, fusion	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	BRAF+EGFR	EGFR:oncogenic mutations and BRAF:fusion	Non-Small Cell Lung Cancer	EGFR inhibitor            	Off-target mechanism	30831205
R2	EGFR	Amplification	Non-Small Cell Lung Cancer	Capmatinib; Crizotinib	Off-target resistance	32034073
R2	EGFR	Amplification	Non-Small Cell Lung Cancer	Osimertinib		32385709, 28625643
R2	EGFR	C797S, C797G	Non-Small Cell Lung Cancer	Afatinib		32206559
R2	EGFR	C797S, C797G	Non-Small Cell Lung Cancer	Osimertinib		25964297; 30073261
R2	EGFR	D761Y	Non-Small Cell Lung Cancer	Gefitinib	Acquired resistance	17085664, 18981003
R2	EGFR	Exon 20 mutation	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Dacomitinib	On-target resistance	24353160
R2	EGFR	L718V, L718Q, G719	Non-Small Cell Lung Cancer	Osimertinib	OncoKB R2 (concordant)	29506987, 31301016
R2	EGFR	L747P	Non-Small Cell Lung Cancer	Osimertinib	Case report	29673089
R2	EGFR	L747P, L747S	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib		31200815
R2	EGFR	L792H	Non-Small Cell Lung Cancer	Afatinib		32206559
R2	EGFR	R451C, G465R, S464L, I491M, ectodomain mutation	Non-Small Cell Lung Cancer	Panitumumab	Ectodomain mutations	25623215
R2	EGFR	S492R, K467T, G465R, S464L, I491M, ectodomain mutation	Non-Small Cell Lung Cancer	Cetuximab	Ectodomain mutations	22270724, 27929064, 25623215
R2	EGFR	S768_D770dup	Non-Small Cell Lung Cancer	Afatinib		32412152
R2	EGFR	T790M and L792H, T790M and G796R	Non-Small Cell Lung Cancer	Osimertinib		32206559
R2	EGFR	T790M, C797S	Non-Small Cell Lung Cancer	Poziotinib		32412152, 10.1016/j.jtho.2019.08.1801
R2	EGFR	T790M, C797S, C797G	Non-Small Cell Lung Cancer	Dacomitinib		29410323, 32206559
R2	EGFR	V843I	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Dacomitinib		25057940
R2	EGFR+ALK	EGFR:oncogenic mutation and ALK:fusion	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Osimertinib		30957057
R2	EGFR+EGFR	EGFR:T790M and EGFR:C797S and EGFR:T790M-C797S cis-allelic conformation	Non-small cell lung cancer	Osimertinib	On-target resistance	31075545
R2	EGFR+RB1	EGFR:oncogenic mutation and RB1:oncogenic mutation	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Osimertinib	Small-cell transformation	25758528, 30550363
R2	EGFR+RET	EGFR:oncogenic mutation and RET:fusion	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Osimertinib		30257958, 30957057
R2	EGFR+ROS1	EGFR:oncogenic mutation and ROS1:fusion	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Osimertinib		29935846
R2	EGFR+TP53	EGFR:oncogenic mutation and TP53:oncogenic mutation	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Osimertinib	Small-cell transformation	30550363
R2	ERBB2	A775_G776insYVMA	Solid tumours; Non-Small Cell Lung Cancer	Afatinib; Dacomitinib		31588020
R2	ERBB2	Amplification	Non-Small Cell Lung Cancer	Erlotinib; Gefitinib	Off-target mechanism	23470965
R2	ERBB2	Exon 20 insertion except G778ins, S779ins, P780ins	Solid tumours; Non-Small Cell Lung Cancer	Afatinib; Dacomitinib; Neratinib; Pyrotinib		31588020
R2	ERBB3	Amplification	Non-Small Cell Lung Cancer	Capmatinib	Off-target resistance	32034073
R2	FGFR3	Fusion	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	KRAS	Amplification, G12D	Non-Small Cell Lung Cancer	Crizotinib	Off-target resistance	32034073
R2	KRAS	Oncogenic mutations	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	KRAS+MET	MET:exon 14 skipping mutation and KRAS:Oncogenic mutations	Non-Small Cell Lung Cancer	Crizotinib		30352902
R2	MET	Amplification	Non-Small Cell Lung Cancer	Gefitinib; Erlotinib; Afatinib; Dacomitinib; Osimertinib		30676858
R2	MET	D1228N, D1228	Non-Small Cell Lung Cancer	Capmatinib; Tepotinib; Savolitinib		32034073
R2	MET	H1094Y, L1195V	Non-Small Cell Lung Cancer	Glesatinib		32034073
R2	MET	L1195V, Y1230, D1228N, D1228, D1246, Y1248, G1163	Non-Small Cell Lung Cancer	Crizotinib	Strong evidence for Crizotinib. Capmatinib inferred	28522754, 27987579, 32306194, 32034073
R2	NRG1	Overexpression	Non-Small Cell Lung Cancer	Seribantumab + Docetaxel	No PFS improvement in EGFR wt NSCLC	10.1200/JCO.2019.37.15_suppl.9036
R2	PIK3CA	Oncogenic mutation	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	RET	Fusion	Non-Small Cell Lung Cancer	Osimertinib	Off-target mechanism	23470965
R2	RET	KIF5B-RET fusion	Non-Small Cell Lung Cancer	Agerafenib		31710864
R2	ROS1	E1395G, L1947R, G1971E, S1986Y, S1986F, L2026M, G2032R, D2033N, S2060G, V2098U, L2155S	Non-Small Cell Lung Cancer	Crizotinib		26372962, 31395437
R2	ROS1	F2004C, F2075V, D2113G	Non-Small Cell Lung Cancer	Cabozantinib		26372962, 31395437, 25351743
R2	ROS1	G2032R	Non-Small Cell Lung Cancer	Lorlatinib		26372962, 31395437
R2	ROS1	G2032R, D2033N	Non-Small Cell Lung Cancer	Ensartinib		26372962, 31395437
R2	ROS1	L1951R, G2032R, D2033N, G2101A, L2155S	Non-Small Cell Lung Cancer	Ceritinib		26372962, 31395437
R2	ROS1	L1951R, L2026M, G2032R, D2033N	Non-Small Cell Lung Cancer	Brigatinib		26372962, 31395437
R2	ROS1	L2026M, G2032R	Non-Small Cell Lung Cancer	AZD3463		26372962, 31395437
R2	ROS1	L2026M, G2032R, D2033N	Non-Small Cell Lung Cancer	Entrectinib		26372962, 31395437
R2	STK11+KRAS	STK11:Oncogenic mutations AND KRAS:Oncogenic mutations	Non-Small Cell Lung Cancer	Anti-PD-1 monoclonal antibody; Anti-PD-L1 monoclonal antibody	Pre-clinical study	29773717
